Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms.

ABSTRACT: The ability of monoclonal antibodies (mAbs) to target specific antigens with high precision has led to an increasing demand to generate them for therapeutic use in many disease areas. Historically, the discovery of therapeutic mAbs has relied upon the immunization of mammals and various in vitro display technologies. While the routine immunization of rodents yields clones that are stable in serum and have been selected against vast arrays of endogenous, non-target self-antigens, it is often difficult to obtain species cross-reactive mAbs owing to the generally high sequence similarity shared across human antigens and their mammalian orthologs. In vitro display technologies bypass this limitation, but lack an in vivo screening mechanism, and thus may potentially generate mAbs with undesirab

SUBMITTER: Abdiche YN 

PROVIDER: S-EPMC4966639 | biostudies-literature | 2016 Feb-Mar

REPOSITORIES: biostudies-literature